Is Balchem (BCPC) overvalued or fairly valued?

MarketChacha shows Balchem's valuation in context — a trailing P/E of about 33.7, a forward P/E of about 27.3, a price-to-book of about 4.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Balchem's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.49×) from reported figures — education, not a rating.

What is Balchem's revenue?

Balchem reported revenue of $1.0B for FY2025, with net profit of $154.8M, per official filings.

What is the share price of Balchem (BCPC)?

Balchem last traded at $171.62 (+0.7% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Balchem

BCPC · NYSE · Materials · United States

Snapshot

TickerBCPC

ExchangeNYSE

SectorMaterials

IndustrySpecialty Chemicals

CountryUnited States

Employees1,379

HeadquartersMontvale, United States

Websitewww.balchem.com

Filings tracked14

About Balchem

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

Who owns it

Insiders0.5%
Institutions93.4%
Public & other6.1%

563 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.57%
Vanguard Portfolio Management LLC6.97%
Vanguard Capital Management LLC4.53%
State Street Corporation4.02%
Geode Capital Management, LLC3.52%
Conestoga Capital Advisors, LLC3.41%
Morgan Stanley2.62%
Geneva Capital Management LLC2.14%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.49×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.8% → 14.9%

Margin has expanded by about 3.2 points — the business is getting more profitable.

Growth qualityrev 6% · PAT 19%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $287.8M · EPS 1.47

Est. earnings growth +11.8%

Next fiscal year

Rev $1.2B · EPS 6.27

Est. earnings growth +7.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.0B

Net margin

14.9%

ROE

12.3%

Revenue CAGR (2y)

+6.0%

Profit CAGR (2y)

+19.4%

EPS (FY2025)

4.75

Net profit (FY2025)

$154.8M

Ask MarketChacha about BCPC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.0B	$154.8M	4.75	14.9%	12.3%
FY2024	$953.7M	$128.5M	3.93	13.5%	11.2%
FY2023	$922.4M	$108.5M	3.35	11.8%	10.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$284.0M	$44.6M	1.39	15.7%
2026Q1	$270.7M	$40.3M	1.25	14.9%
2025Q4	$263.6M	$39.2M	1.21	14.9%
2025Q3	$267.6M	$40.3M	1.24	15.1%
2025Q2	$255.5M	$38.3M	1.17	15.0%
2025Q1	$250.5M	$37.1M	1.13	14.8%
2024Q4	$240.0M	$33.6M	1.03	14.0%
2024Q3	$239.9M	$33.8M	1.03	14.1%
2024Q2	$234.1M	$32.1M	0.98	13.7%
2024Q1	$239.7M	$29.0M	0.89	12.1%
2023Q4	$228.7M	$26.6M	0.82	11.7%
2023Q3	$229.9M	$29.1M	0.90	12.6%
2023Q2	$231.3M	$30.1M	0.93	13.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/31/2026
8-K — Results of operations, Exhibits
SEC7/31/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC7/27/2026material
8-K — Shareholder vote results
SEC6/22/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Results of operations, Exhibits
SEC2/20/2026material
10-K filing
SEC2/20/2026
8-K — Executive/director change, Exhibits
SEC2/19/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/10/2025material
8-K — Results of operations, Exhibits
SEC10/21/2025material
10-Q filing
SEC10/21/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.